• Kristine M Erlandson, Linda N Geng, Caitlin A Selvaggi, Tanayott Thaweethai, Peter Chen, Nathan B Erdmann, Jason D Goldman, Timothy J Henrich, Mady Hornig, Elizabeth W Karlson, Stuart D Katz, C Kim, Sushma K Cribbs, Adeyinka O Laiyemo, Rebecca Letts, Janet Y Lin, Jai Marathe, Sairam Parthasarathy, Thomas F Patterson, Brittany D Taylor, Elizabeth R Duffy, Monika Haack, Boris Julg, Gabrielle Maranga, Carla Hernandez, Nora G Singer, Jenny Han, Priscilla Pemu, Hassan Brim, Hassan Ashktorab, Alexander W Charney, Juan Wisnivesky, Jenny J Lin, Helen Y Chu, Minjoung Go, Upinder Singh, Emily B Levitan, Paul A Goepfert, Janko Ž Nikolich, Harvey Hsu, Michael J Peluso, J Daniel Kelly, Megumi J Okumura, Valerie J Flaherman, John G Quigley, Jerry A Krishnan, Mary Beth Scholand, Rachel Hess, Torri D Metz, Maged M Costantine, Dwight J Rouse, Barbara S Taylor, Mark P Goldberg, Gailen D Marshall, Jeremy Wood, David Warren, Leora Horwitz, Andrea S Foulkes, Grace A McComsey, and RECOVER-Adult Cohort.
• Department of Medicine, Division of Infectious Diseases, University of Colorado, Anschutz Medical Campus, Aurora, Colorado (K.M.E.).
• Ann. Intern. Med. 2024 Sep 1; 177 (9): 120912211209-1221.

BackgroundThere are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC).ObjectiveTo investigate clinical laboratory markers of SARS-CoV-2 and PASC.DesignPropensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024).Setting83 enrolling sites.ParticipantsRECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection.MeasurementsParticipants completed questionnaires and standard clinical laboratory tests.ResultsAmong 10 094 participants, 8746 had prior SARS-CoV-2 infection, 1348 were uninfected, 1880 had a PASC index of 12 or higher, and 3351 had a PASC index of zero. After propensity score adjustment, participants with prior infection had a lower mean platelet count (265.9 × 109 cells/L [95% CI, 264.5 to 267.4 × 109 cells/L]) than participants without known prior infection (275.2 × 109 cells/L [CI, 268.5 to 282.0 × 109 cells/L]), as well as higher mean hemoglobin A1c (HbA1c) level (5.58% [CI, 5.56% to 5.60%] vs. 5.46% [CI, 5.40% to 5.51%]) and urinary albumin-creatinine ratio (81.9 mg/g [CI, 67.5 to 96.2 mg/g] vs. 43.0 mg/g [CI, 25.4 to 60.6 mg/g]), although differences were of modest clinical significance. The difference in HbA1c levels was attenuated after participants with preexisting diabetes were excluded. Among participants with prior infection, no meaningful differences in mean laboratory values were found between those with a PASC index of 12 or higher and those with a PASC index of zero.LimitationWhether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined.ConclusionOverall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC.Primary Funding SourceNational Institutes of Health.

23 keywords...

hide…